Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

AbbVie Inc. (ABBV)

144.95   0.11 (0.08%) 02-03 14:57
Open: 145.92 Pre. Close: 144.84
High: 146.78 Low: 144.86
Volume: 3,211,485 Market Cap: 256,341(M)

Technical analysis

as of: 2023-02-03 2:44:48 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 185.34     One year: 196.35
Support: Support1: 143.44    Support2: 119.34
Resistance: Resistance1: 158.68    Resistance2: 168.11
Pivot: 148.1
Moving Average: MA(5): 145.99     MA(20): 150.94
MA(100): 151.48     MA(250): 150.33
MACD: MACD(12,26): -3.7     Signal(9): -3.4
Stochastic oscillator: %K(14,3): 13.6     %D(3): 13.4
RSI: RSI(14): 30.4
52-week: High: 175.91  Low: 134.08
Average Vol(K): 3-Month: 5,397 (K)  10-Days: 5,009 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ABBV ] has closed above bottom band by 19.2%. Bollinger Bands are 20.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 146.21 - 147.04 147.04 - 147.94
Low: 141.1 - 142.02 142.02 - 143.03
Close: 143.09 - 144.7 144.7 - 146.46

Company Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Headline News

Fri, 03 Feb 2023
Should You Buy AbbVie Inc (ABBV) Stock on Friday? - InvestorsObserver

Fri, 03 Feb 2023
ABBV: The 5 Best Stocks to Invest $1,000 in Right Now - StockNews.com

Fri, 03 Feb 2023
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You ... - Nasdaq

Fri, 03 Feb 2023
Is AbbVie (ABBV) an Attractive Investment Option? - Yahoo Finance

Thu, 02 Feb 2023
ABBV March 24th Options Begin Trading - Nasdaq

Thu, 02 Feb 2023
ABBV: These 3 Dividend Stocks Are Worth Investing In - StockNews.com

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 1,770 (M)
Shares Float 1,770 (M)
% Held by Insiders 0.1 (%)
% Held by Institutions 70.8 (%)
Shares Short 11,960 (K)
Shares Short P.Month 13,580 (K)

Stock Financials

EPS 7.5
EPS Est Next Qtl 1.44
EPS Est This Year 5.53
EPS Est Next Year 6.55
Book Value (p.s.) 9.03
Profit Margin (%) 23.1
Operating Margin (%) 37.2
Return on Assets (ttm) 9.2
Return on Equity (ttm) 90.6
Qtrly Rev. Growth 3.2
Gross Profit (p.s.) 21.96
Sales Per Share 32.66
EBITDA (p.s.) 16.83
Qtrly Earnings Growth 24.2
Operating Cash Flow 22,590 (M)
Levered Free Cash Flow 20,200 (M)

Stock Valuations

PE Ratio 19.34
PEG Ratio -3.6
Price to Book value 16.05
Price to Sales 4.44
Price to Cash Flow 11.36

Stock Dividends

Dividend 1.48
Forward Dividend 0
Dividend Yield 1%
Dividend Pay Date 2022-02-14
Ex-Dividend Date 2022-01-12
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.